Cefroxadine is clinically used for the treatment of infections caused by susceptible strains, including bronchitis, pharyngitis, tonsillitis, cystitis, furunculosis, carbuncles, folliculitis, cellulitis, impetigo, and scarlet fever. It exhibits broad-spectrum bactericidal activity in vitro against Gram-positive bacteria such as Staphylococcus spp., as well as Gram-negative bacteria including Haemophilus influenzae, Escherichia coli, and Klebsiella spp. Its antibacterial potency is stronger than that of cefalexin due to its high affinity for penicillin-binding proteins LA and LBs.